|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
DETREND PRICE OSCILLATOR
Trading: SELL @ $0.19
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Cogstate (ASX:CGS) currently has a confirmed downtrend. Price is currently below the displaced moving average for CGS Currently, the return on DPO20 is -2.6%.
The Detrended Price Oscillator (DPO) is an indicator designed to remove trend from price and make it easier to identify cycles. DPO does not extend to the last date because it is based on a displaced moving average. However alignment with the most recent is not an issue because DPO is not a momentum oscillator. Instead DPO is used to identify cycle’s highs/lows and estimate cycle length.
Calculation: Detrended Price Oscillator (DPO):
1) Price (X/2 + 1) periods ago minus X-period simple moving average.
Where X is the number of periods;
PROFILE: Cogstate (CGS.AX)
Stock Exchange: ASX
Ticker Codes: | CGS.AX | ASX:CGS |
Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain injury applications primarily in Australia, the United States, and Europe. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of disease and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations. As of June 30, 2017, it had participated in approximately 1,200 academic research studies in approximately 70 indications. The Healthcare segment provides Cognigram, a system that enables regular and standardized assessment of patients to detect cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is headquartered in Melbourne, Australia.
|ATL ASX 20||0.43||10.4||117,204||-0.02||BEARISH|
|BSA Broadcast Services Australia||0.34||7.9||824,051||-0.01||BEARISH|
|SUL Super Cheap Auto||9.75||7.9||2,023,965||-0.41||BEARISH|
|SWM Seven West Media||0.4||6.7||22,528,171||-0.1||BEARISH|
|EWC Energy World Corporation||0.07||5.8||402,315||-0.03||BEARISH|
|CAJ Capitol Health||0.23||4.5||159,441||-0.02||BEARISH|
|MOY Millennium Minerals||0.13||4.2||1,692,090||-0.03||BEARISH|